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Abstract
Background: The increasing levels of Plasmodium falciparum resistance to chloroquine (CQ) in
Thailand have led to the use of alternative antimalarials, which are at present also becoming
ineffective. In this context, any strategies that help improve the surveillance of drug resistance,
become crucial in overcoming the problem.
Methods: In the present study, we have established the in vitro sensitivity to CQ, mefloquine (MF),
quinine (QUIN) and amodiaquine (AMQ) of 52 P. falciparum isolates collected in Thailand, and
assessed the prevalence of four putative genetic polymorphisms of drug resistance, pfcrt K76T,
pfmdr1 N86Y, pfmdr1 D1042N and pfmdr1 Y1246D, by PCR-RFLP.
Results: The percentage of isolates resistant to CQ, MF, and AMQ was 96% (50/52), 62% (32/52),
and 58% (18/31), respectively, while all parasites were found to be sensitive to QUIN. In addition,
41 (79%) of the isolates assayed were resistant simultaneously to more than one drug; 25 to CQ
and MF, 9 to CQ and AMQ, and 7 to all three drugs, CQ, MF and AMQ. There were two significant
associations between drug sensitivity and presence of particular molecular markers, i) CQ
resistance / pfcrt 76T (P = 0.001), and ii) MF resistance / pfmdr1 86N (P < 0.001)
Conclusions: i) In Thailand, the high levels of CQ pressure have led to strong selection of the pfcrt
76T polymorphism and ii) pfmdr1 86N appears to be a good predictor of in vitro MF resistance.
Background
Malaria due to Plasmodium falciparum affects 300 million
people and claims an estimated 1.5 million lives every
year. Our present inability to synthesise a fully protective
vaccine means that chemotherapy stands as the only effec-
tive measure in the control of the disease. However, in
many parts of the world the parasite P. falciparum has be-
come resistant to most drugs presently used [1], seriously
undermining efforts for controlling malaria.
Chloroquine (CQ) has long been the drug of choice for
the treatment of malaria; however, CQ-resistant parasites
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are now present in most areas where malaria is endemic
[2]. Chloroquine resistance is especially well established
in Thailand, after having been first described in that coun-
try in the late 1950's [3]. The decline in the efficacy of
chloroquine has led to the use of alternative antimalarials,
such as antifolates, mefloquine and artemisinin deriva-
tives, but parasite resistance to these drugs is also becom-
ing a real problem [2]. In this context, understanding the
genetic basis of drug resistance is essential for implement-
ing rational measures to overcome the problem.
Although significant progress has been made in trying to
understand how resistance to CQ may occur, many as-
pects of it remain unclear, and the genetic mechanisms re-
sponsible for mefloquine and quinine resistance are
largely unknown. Nevertheless, two main genes have been
implicated in quinoline resistance; the pfmdr1 (P. falci-
parum multi-drug resistance1) and the Pfcrt (P. falciparum
chloroquine resistance transporter). There is evidence from
the analysis of a genetic cross which indicates that point
polymorphisms in the pfmdr1 gene may modulate sensi-
tivity to both mefloquine (MF) and artemisinin in P. falci-
parum[4]. Furthermore, recent genetic transfection work
has suggested that single nucleotide polymorphisms in
the pfmdr1 gene encoding changes in aminoacids 1034,
1042 and 1246 can influence parasite responses to meflo-
quine, quinine and halofantrine as well as to the structur-
ally unrelated drug artemisinin, and modulate sensitivity
to chloroquine depending on the genetic background of
the parasites strains [5]. However, chloroquine resistance
was shown to segregate independently of the pfmdr1 gene,
following a genetic cross between a CQ-sensitive parasite,
P. falciparum HB3, and a CQ-resistant one, Dd2 [6], and
the absence of a clear association between pfmdr1 and
chloroquine responses in natural parasite populations [7–
15], strongly suggests the involvement of other gene(s).
Recently, detailed linkage analysis and fine chromosome
mapping of progeny clones of the HB3  Dd2 cross has al-
lowed the identification of another gene, pfcrt, in which a
mutation at aminoacid 76 (pfcrt K76T) is highly correlated
with increased CQ tolerance among field parasite isolates
of P. falciparum[16–24]. In addition, a causal relationship
between pfcrt 76T and chloroquine resistance has been
confirmed by genetic transfection experiments [16].
The study of the correlation between drug resistance in
natural parasite populations and genetic polymorphisms
may allow the development of molecular tools to help
predict responses to drugs and, as mentioned above, the
pfcrt and pfmdr1 genes have been identified as putative
markers of quinoline resistance. In the present work we
have investigated possible associations between four mo-
lecular markers in these genes and sensitivity to chloro-
quine, mefloquine, quinine (QUIN) and amodiaquine
(AMQ) of P. falciparum parasites collected in Thailand.
Methods
Study site and method of parasite collection
After confirmation of P. falciparum infection by micro-
scopical observation of thin and thick Giemsa-stained
blood films, approximately 20 l of blood were collected
by finger-prick from consenting subjects living in 4 differ-
ent areas of Thailand where malaria is highly endemic; the
Tak province (North-western Thailand), Kanchanaburi
(Western Thailand: Thai-Myanmar border), Chonburi
(Eastern Thailand), Chantaburi and Trat (Eastern Thai-
land: Thai-Cambodia border). Samples were placed in
sterile 1.5 ml micro-centrifuge tubes, together with 0.5 ml
of transport medium (10 ml RPMI 1640 complete medi-
um without serum, plus 20 l of heparin 5000 i.u./ml),
carried to Chulalongkorn University of Bangkok on the
day of collection, at ambient temperature and placed in in
vitro culture, following established procedures [25].
Parasite phenotyping (micro-tests)
Assessment of P. falciparum susceptibility to CQ, MF,
QUIN and AMQ was performed according to the M.I.C.
test [26,27], whereby samples were exposed to a range of
concentrations of the four drugs, in microtitre culture
plates, for 72 hours, with daily changes of medium (in the
presence or absence of drugs). After this period, thin film
Giemsa-stained preparations from each culture plate well
were observed under light microscopy for the presence of
parasites. The results were expressed in "minimum inhib-
iting concentration" (M.I.C.) units, i.e., the lowest drug
concentration required to kill all or nearly all parasites
(I.C.99) after 72 hours [26,27].
Parasite reference strains of known sensitivity to the drugs
concerned were tested in parallel to all field-collected iso-
lates. In this manner, the drug response of each isolate was
determined by comparison of the M.I.C. between each
sample and the relevant reference strains. Accordingly,
samples tested for CQ, MF, QUIN and AMQ responses
were clustered into two groups; sensitive (S) or resistant
(R) based on sensitivity thresholds established in previous
studies [26–29].
Genotyping by PCR-RFLP
Genomic DNA was extracted prior to drug testing, by a
standard phenol:chloroform DNA extraction method,
precipitated with absolute ethanol and stored in TE Buffer
(Tris-EDTA), following established protocols [30]. The re-
sulting DNA was used as template in 50 l PCR reactions,
containing 1 M of each oligonucleotide primer, 1  PCR
buffer (Promega™), 2.5 mM MgCl2, 0.2 mM dNTP's and
0.025 U/l of Promega™ Taq DNA polymerase. According-
ly, a fragment of the pfcrt gene containing codon 76 was
amplified by PCR using a Nested-PCR approach. For am-
plification of DNA fragments containing pfmdr1 polymor-
phisms we used oligonucleotide primers publishedMalaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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elsewhere [31], as well as newly designed ones. In this
manner, the fragments of the pfmdr1 gene containing co-
dons 86 and 1246 were amplified in a single-step PCR,
whereas the sequence of codon pfmdr1 1042 was deter-
mined following amplification by semi-nested PCR. All
primer sequences and respective PCR conditions are pre-
sented in Table 1.
Restriction enzymes generating RFLPs
Following amplification of the fragments concerned, pol-
ymorphisms in the pfcrt and pfmdr1 genes were assessed as
follows: pfcrt 76K and pfmdr1 86N were detected by incu-
bation of the corresponding PCR fragments with ApoI (r/
aatty), pfmdr1 1042N was detected using AsnI (at/taat),
and pfmdr1 1246Y was determined by incubation with
EcoRV (gat/atc). Endonucleases ApoI, AsnI and EcoRV had
been obtained from New England BioLabs™, Roche Mo-
lecular Biochemicals™ and Stratagene™ respectively, and
incubations were setup following the manufacturers in-
structions. Appropriate control DNA of samples with
known pfcrt and pfmdr1 sequences was used in parallel
with field-collected parasite isolates in every PCR-RFLP
protocol; these were 3D7 (genotype pfcrt 76K, pfmdr1
86N,  pfmdr1 1042N, pfmdr1 1246D), HB3 (genotype
pfmdr1 1042D), Dd2 (genotype pfcrt 76T, pfmdr1 86Y)
and 180/92 (genotype pfmdr1 1246Y). The products re-
sulting from restrictions of pfmdr1 1042 were resolved in
8% acrylamide gels, whereas pfmdr1 86, pfmdr1 1246 and
pfcrt 76 digests were run on 2% agarose gels, with both
types of gels made in 1  TBE buffer. All gels were stained
with ethidium bromide and visualised under UV (ultravi-
olet) transillumination.
Statistical analysis of the association between pfcrt and 
pfmdr1 markers and drug responses
We searched for statistically significant associations be-
tween sensitivity to each of the drugs among all isolates
and the presence of each of the particular markers includ-
ed in our study by using Fisher's Exact Test (2-tailed) after
having arranged the data in 2  2 contingency tables
(mixed infections were excluded from this analysis). An
association between a particular marker and resistance to
a given drug was considered to be significant if the P value
was found to be lower than 0.05 (P < 0.05).
Results
Responses to drugs
In total, 52 samples were analysed in vitro for their suscep-
tibility to chloroquine, mefloquine and quinine, and 31
for amodiaquine. The results of these tests are presented
in Table 2.
Pfcrt and pfmdr1 genotypes
The pfcrt 76 PCR primers amplified a sub-fragment of the
gene comprising 479 nucleotides, containing both a mon-
omorphic and a polymorphic ApoI restriction site. In this
manner, incubation of this fragment with endonuclease
ApoI generated either 3 fragments of 122, 124 and 233
base-pairs (b.p.), or 2 fragments of 233 and 246 b.p., if K
or T were present respectively (Figure 1). The PCR of
pfmdr1 86 amplified a fragment of 504 b.p., within which
Table 1: Polymerase Chain Reaction for amplification of fragments containing pfcrt and pfmdr1 gene polymorphisms
Primer Sequence (5'  3') PCR
Pfcrt 76
1st round sense CAAGAAGGAAGTAAGTATCCAAAAATGG 94C, 30''; 56C, 30''; 60C, 60''; 45 cycles
Antisense GTAGTTCTTGTAAGACCTATGAAGGC
Nested sense GCAAAAATGACGAGCGTTATAGAG 94C, 30''; 59C, 30''; 60C, 60''; 45 cycles
Antisense CTGAACAGGCATCTAACATGGATATAGC
Pfmdr1 86
Sense ATGGGTAAAGAGCAGAAAGAG 94C, 30''; 53C, 30''; 68C, 60''; 10 cycles, followed 
by 94C, 30''; 50C, 30''; 68C, 60'', 35 cycles
Antisense CGTACCAATTCCTGAACTCAC
Pfmdr1 1042
1st round sense TATGTCAAGCGGAGTTTTTGC 94C, 30''; 50C, 30''; 68C, 60''; 45 cycles
Antisense TCTGAATCTCCTTTTAAGGAC
Semi-nested sense GTAAATGCAGCTTTATGGG 94C, 30''; 50C, 30''; 68C, 60''; 45 cycles
Antisense TCTGAATCTCCTTTTAAGGAC
Pfmdr1 1246
Sense CTACAGCAATCGTTGGAGAAA 94C, 30''; 53C, 30''; 68C, 60''; 10 cycles, followed 
by 94C, 30''; 50C, 30''; 68C, 60'', 35 cycles
Antisense GCTCTAGCTATAGCTATTCTCMalaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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the presence of asparagine (N) was determined by incuba-
tion with ApoI, originating segments of 255 and 249 b.p.,
which resolved as a single band in 2% agarose gels (Figure
1). For detection of 1042 polymorphisms (N or D) the
188 b.p. fragment obtained by PCR could be restricted
with endonuclease AsnI, after which 3 segments were ob-
tained of 116, 46 and 26 b.p. if 1042N were present in the
sample, and two fragments of 162 and 26 b.p. in the pres-
ence of the alternative aminoacid (as with pfcrt 76, one of
the restriction sites for AsnI within this segment is also
monomorphic, therefore always resulting in at least one
cut) (Figure 1). Codon 1246 polymorphisms (D or Y)
were assayed following incubation of the corresponding
508 b.p. PCR product with EcoRV, which produced 2 frag-
ments of 268 and 240 b.p. if the target DNA contained ty-
rosine (Y) (Figure 1). All data resulting from this analysis
is compiled in Table 3, where allele frequencies for each
of the markers are shown.
Association between pfcrt and pfmdr1 markers and re-
sponses to drugs
Two significant correlations were detected between the
presence of a particular marker and in vitro outcomes (Ta-
bles 4 and 5); one between CQ resistance and the presence
of pfcrt 76T (P = 0.001) and the other, between MF resist-
ance and the presence of pfmdr1 86N (P < 0.001). There
was an evident lack of an association between AMQ re-
sponses and all of the markers studied (Table 6), a fact
that was corroborated after statistical analysis (data not
shown). In addition, since all isolates proved to be qui-
nine sensitive, any correlations between response to this
drug and corresponding genotypes could not be estab-
lished. The data of the in vitro tests for the 4 drugs, and
corresponding genotypes is compiled in Table 7.
Discussion
The increasing failure rates of several antimalarial drugs in
the majority of malaria-affected areas means that close
monitoring of the epidemiology and dynamics of drug re-
sistance are necessary if we are to implement measures to
circumvent the problem. The identification and valida-
tion of easy, rapid molecular markers of drug resistance
would greatly facilitate this process, and would allow us to
overcome difficulties in the use of traditional methods for
assaying drug sensitivity.
In Thailand, CQ resistance was first reported more than
forty years ago [3], and after ten years, resistance to chlo-
roquine had become so widespread that use of the drug
against  P. falciparum was abandoned. At present, even
though the drug is used only against P. vivax, it is perhaps
not surprising to find that most P. falciparum are largely
unaffected by CQ. Our in vitro observations show a near
total prevalence of CQR (96%) in the present study area,
confirming what has been widely reported [1]. Among all
CQR isolates tested in our study, the presence of pfcrt 76T
was universal (P = 0.001), indicating complete selection
of this polymorphism by the drug, a result that is in agree-
ment with recently published work not only from Thai-
originated parasites [22], but also from parasites of differ-
ent areas of the globe [32].
The correlation between pfmdr1 genotypes and quinoline
resistance has often generated conflicting results; al-
though it has been suggested that pfmdr1 86Y can be cor-
related with increased CQ resistance in parasites which
originated from different areas of the world [33–36], oth-
er field studies have not corroborated these findings [7–
15], and the results of a P. falciparum genetic cross indicat-
Table 2: Results of in vitro drug tests (CQ-chloroquine; MF-mefloquine; QUIN-quinine; AMQ-amodiaquine; S-sensitive; R-resistant)
CQ MF QUIN AMQ CQ+MF only CQ+AMQ only MF+AMQ only CQ+MF+A
MQ
S 4% (2/52) 38% (20/52) 100% (52/52) 42% (13/31) - - - -
R 96% (50/52) 62% (32/52) - 58% (18/31) 48% (25/52) 29% (9/31) -(0/31) 23% (7/31)
Table 3: Frequencies of allelic polymorphisms in the pfcrt and pfmdr1 genes
Pfcrt Pfmdr1
Allele 76K 76T Mixed 86N 86Y Mixed 1042N 1042D Mixed 1246D 1246Y Mixed
Frequency .04 .83 .13 .60 .23 .17 .92 .08 0 .92 .02 .06Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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ed that CQR did not depend on the pfmdr1 gene [6]. Our
present findings do not implicate pfmdr1 86 in CQ resist-
ance in Thailand, since the presence of both N and Y in
our samples was largely independent of their CQ re-
sponse, indicating that chloroquine does not appear to ex-
ert selective pressure on this area of the gene. Interestingly
though, pfmdr1 1042D and pfmdr1 1246N, previously as-
sociated with increased CQ sensitivity following genetic
transfection experiments [5], were largely absent in our
samples, possibly suggesting a mechanism of chloroquine
resistance that may in part depend on the presence of the
alternative polymorphic alleles, pfmdr1 1042N and
pfmdr1 1246D, respectively.
Mefloquine was introduced in Thailand in the form of
Fansimef (mefloquine-sulfadoxine-pyrimethamine) dur-
ing 1984 with an initial cure rate of 95%, but MF-resistant
P. falciparum parasites have arisen and present a real threat
to the control of malaria, especially in the Thai/Cambodia
and Thai/Myanmar border areas [37]. In the present work
the prevalence of MF resistance was 62%, indicating a
worrying trend. A correlation between pfcrt 76T and me-
floquine sensitivity would always be difficult to establish,
since the near complete presence of this polymorphism is
likely to have been selected by chloroquine pressure,
whose mechanisms of action and resistance are probably
distinct from those of MF. Earlier work from Thailand and
other areas of the world has indicated that an increase in
the level of mefloquine sensitivity among field isolates of
Figure 1
Agarose (pfmdr1 86, pfmdr1 1246, pfcrt 76), and acrylamide (pfmdr1 1042) gels showing PCR products and corresponding
restriction digests, of control and field-collected samples of P. falciparum. (PCR-RFLP controls – 3D7 (genotype pfcrt 76K,
pfmdr1 86N, pfmdr1 1042N, pfmdr1 1246D), HB3 (genotype pfmdr1 1042D), Dd2 (genotype pfcrt 76T, pfmdr1 86Y) and 180/92
(genotype pfmdr1 1246Y); IV, V and VIII – DNA Molecular Weight Markers IV, Bioline; V and VIII, Roche)Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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Table 4: Plasmodium falciparum isolates listed according to sensitivity to chloroquine (CQ), with corresponding pfcrt and pfmdr1 
markers
pfmdr1
Isolate CQ pfcrt 76 86 1042 1246
T9/94b3 S K Y N D
TM408 S K N N D
T101 R T N N D
T108 R T N N D
T113 R T N N D
T115 R T N N D
T116 R T N N D
T120 R T Y N D
T123 R T N D D
T130 R T N N D
T131 R T N N D
T132 R T N N D
T133 R T N N D
S3 R T Y N D
S64 R T Y N D
S71 R T Y N D
S90 R T Y D D
S118 R T Y N D
S149 R T NY N DY
S151 R KT NY N D
S152 R T Y N D
S153 R T Y N D
S157 R KT NY N D
S160 R KT NY N DY
CH1 R T Y D D
CH3 R T Y D D
CH7 R T N N D
TD2 R T N N D
TD3 R T N N D
TD8 R T N N D
TD14 R T N N D
TD21 R T N N D
TD27 R T N N D
TD49 R T N N D
TD56 R T N N D
TD61 R KT N N D
TD62 R T N N D
TD64 R T N N DY
TD79 R KT N N D
TD134 R T N N D
TD328 R KT N N D
TP4 R T Y N D
TP7 R T NY N D
TP13 R T NY nd D
TP17 R T NY N D
TP18 R T N N D
TP20 R T NY N D
TP21 R KT N nd D
TP26 R T N N D
TP34 R T N N D
TP40 R T N nd Y
RC17 R T NY N D
(S – sensitive; R – resistant; KT, NY and DY – mixed infections; nd – not determined; P = 0.001 for the association between CQR and presence of 
pfcrt 76T, mixed alleles excluded)Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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Table 5: Plasmodium falciparum isolates listed according to sensitivity to mefloquine (MF), with corresponding pfcrt and pfmdr1 markers
pfmdr1
Isolate MF pfcrt 76 86 1042 1246
T9/94b3 S K Y N D
S3 S T Y N D
S64 S T Y N D
S71 S T Y N D
S90 S T Y D D
S118 S T Y N D
S149 S T NY N DY
S151 S KT NY N D
S152 S T Y N D
S153 S T Y N D
S157 S KT NY N D
S160 S KT NY N DY
CH1 S T Y D D
CH3 S T Y D D
TP4 S T Y N D
TP7 S T NY N D
TP13 S T NY nd D
TP17 S T NY N D
TP18 S T N N D
TP40 S T N nd Y
TM408 R K N N D
TP20 R T NY N D
TP21 R KT N nd D
RC17 R T NY N D
T108 R T N N D
T113 R T N N D
T115 R T N N D
T130 R T N N D
T131 R T N N D
T132 R T N N D
TD61 R KT N N D
TD14 R T N N D
T101 R T N N D
T116 R T N N D
T120 R T Y N D
T123 R T N D D
T133 R T N N D
CH7 R T N N D
TD2 R T N N D
TD3 R T N N D
TD8 R T N N D
TD21 R T N N D
TD27 R T N N D
TD49 R T N N DMalaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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TD62 R T N N D
TD134 R T N N D
TD328 R KT N N D
TD56 R T N N D
TD64 R T N N DY
TD79 R KT N N D
TP26 R T N N D
TP34 R T N N D
(S – sensitive; R – resistant; KT, NY and DY – mixed infections; nd – not determined; P < 0.001 for the association between MFR and presence of 
pfmdr1 86N, mixed alleles excluded)
Table 6: Plasmodium falciparum isolates listed according to sensitivity to amodiaquine (AQ), with corresponding pfcrt and pfmdr1 
markers
Pfmdr1
Isolate AQ pfcrt 76 86 1042 1246
S153 S T Y N D
S157 S KT NY N D
S160 S KT NY N DY
TD3 S T N N D
TD49 S T N N D
TD56 S T N N D
TD62 S T N N D
TD79 S KT N N D
TD134 S T N N D
TD328 S KT N N D
TP4 S T Y N D
TP18 S T N N D
TP26 S T N N D
T9/94b3 R K Y N D
TM408 R K N N D
S3 R T Y N D
S118 R T Y N D
S149 R T NY N DY
S151 R KT NY N D
S152 R T Y N D
TD14 R T N N D
TD61 R KT N N D
TD64 R T N N DY
TP7 R T NY N D
TP13 R T NY nd D
TP17 R T NY N D
TP20 R T NY N D
TP21 R KT N nd D
TP34 R T N N D
TP40 R T N nd Y
RC17 R T NY N D
(S – sensitive; R – resistant; KT, NY and DY – mixed infections; nd – not determined)
Table 5: Plasmodium falciparum isolates listed according to sensitivity to mefloquine (MF), with corresponding pfcrt and pfmdr1 markers Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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P. falciparum may be correlated with a mutation in codon
86 of the pfmdr1 gene (N86Y) [38–40]. In the present
work, the occurrence of pfmdr1 86N was significantly as-
sociated with MF resistance as 31/32 resistant isolates car-
ried this polymorphism (P < 0.001), strongly suggesting
that 86N is an important event in the generation of MF re-
sistance and may be a useful marker to monitor MF resist-
ance in this country.
Interestingly, although the prevalence of AMQ resistance
was high (58%), we did not detect a significant correla-
tion between AMQ responses and any of the markers stud-
ied, contrary to what could be expected considering that
AMQ is chemically very similar to CQ. These observations
indicate that the mechanism of action and/or resistance
differ between the two drugs, which may raise interesting
questions about the design of new CQ-derivative com-
pounds.
Quinine is one of the most effective drugs for the treat-
ment of malaria in Thailand. Although the efficacy of this
drug has been reduced, it has not yet become a serious
problem, since the combination with tetracycline increas-
es its cure rate. In fact, P. falciparum quinine sensitivity was
total in all regions covered by our study, showing that de-
spite its adverse side effects, quinine can still be used as a
reliable resource of malaria therapy in Thailand. The rea-
sons for the long-lasting efficacy of quinine may be man-
yfold, but its explanations lie outside the scope of this
article. Most importantly, quinine may prove especially
valuable in the treatment of multi-drug resistant Falci-
parum malaria, which we found to be largely present in
our study as 41 out of 52 isolates were found to be resist-
ant to more than one compound and 7 were unaffected by
all drugs (CQ, MF and AMQ) except quinine.
Conclusions
Taken together, our results seem to be suggesting that CQ
and MF are the major selective forces on the pfcrt and
pfmdr1 genes, whereby the presence of pfcrt 76T, and pos-
sibly pfmdr1 1042N and pfmdr1 1246D in Thai-originated
parasites has been selected by chloroquine pressure. The
pfmdr1 86N mutation seems to be important only for me-
floquine resistance, and may represent a useful marker for
monitoring resistance in this country, although its valida-
tion may require in vivo correlates and the analysis of a
larger number of samples.
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mixed infections; shaded boxes indicate the two cases where there was a significant association between the presence of a particular marker and 
drug sensitivity: pfcrt 76T/CQR, P = 0.001 and pfmdr1 86N/MFR, P < 0.001)Malaria Journal 2002, 1 http://www.malariajournal.com/content/1/1/12
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